Register or Sign in to Save this opportunity, or Send an Inquiry.
DWP05195, DWP418_Daewoong Pharmaceutical Co., Ltd.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Novel Neuropathic Pain Therapeutics : DWP05195, Oncolytic Adenovirus Cancer Gene Therapy : DWP418
Send an Inquiry

1. Novel Neuropathic Pain Therapeutics: DWP05195


Indication: Neuropathic Pain


u  Caused by primary lesion or dysfunction of the nervous system

u  No effective pharmacological solution      


Candidate Profile


u  Potent pharmacological effect on Neuropathic Pain (TRPV1 antagonist)

u  No clinical adverse effect

u  Favorable PK profile

u  Ease of synthesis

u  Solid patent profiles


Development Status 


u  Clinical Phase II

u  Completed by 4Q 2011


2.  Oncolytic Adenovirus Cancer Gene Therapy: DWP418


Indication: Refractory Solid Tumors


Candidate Profile


u  Oncolytic adenovirus (defined as the killing of tumor cells by virus infection, replication)

ü  Cancer-specific replication by novel modified hTERT promoter

ü  Viral spreading effect of Relaxin

u  Therapeutic potency shown in both in vitro & in vivo studies

ü  Tumor growth was suppressed dose-dependently with a single dose injection

ü  Tumor growth was suppressed according to the injection frequency

u  Reduced side effects due to cancer-specific proliferation


Development Status 


u  Clinical Phase I

u  Completed by 1Q 2011

Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS

Opportunity Contact